» Articles » PMID: 33916900

Obesity Does Not Interfere with the Cholesterol-Lowering Effect of Plant Stanol Ester Consumption (as Part of a Heart-Healthy Diet)

Overview
Date 2021 Apr 30
PMID 33916900
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Dietary modifications including plant stanol ester consumption are recommended measures to control serum and low-density lipoprotein (LDL)-cholesterol concentrations, but obesity can affect their responses. We investigated whether body mass index (BMI) affects serum cholesterol levels during plant stanol (mainly sitostanol) ester consumption. This ad hoc analysis was based on earlier results of a cross-over, randomized controlled trial of postmenopausal women consuming rapeseed oil-based margarine without or with plant stanol ester (3 g plant stanols/day) for seven weeks. We classified the subjects as normal-weight (BMI ≤ 25 kg/m, = 9, mean 22.6 kg/m) or overweight/obese (BMI > 25 kg/m, = 11, mean 28.4 kg/m), and recalculated the results, focusing on cholesterol absorption, cholesterol synthesis, and fecal steroid outputs. Serum cholesterol levels were similar in the groups during the control diet. Plant stanol ester reduced serum cholesterol by 0.63 ± 0.19 mmol/L (11%) in normal-weight and by 0.75 ± 0.13 mmol/L (12%) in overweight/obese subjects ( < 0.05 for both), and cholesterol absorption was reduced in both groups. However, relative and dietary cholesterol absorption were more effectively reduced in normal-weight subjects. In conclusion, overweight/obesity did not interfere with the serum cholesterol response to plant stanol ester consumption despite substantial differences in cholesterol metabolism between the groups.

Citing Articles

Heart-healthy diets including phytostanol ester consumption to reduce the risk of atherosclerotic cardiovascular diseases. A clinical review.

Simonen P, Nylund L, Vartiainen E, Kovanen P, Strandberg T, Oorni K Lipids Health Dis. 2024; 23(1):341.

PMID: 39434087 PMC: 11492639. DOI: 10.1186/s12944-024-02330-7.

References
1.
Boren J, Chapman M, Krauss R, Packard C, Bentzon J, Binder C . Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020; 41(24):2313-2330. PMC: 7308544. DOI: 10.1093/eurheartj/ehz962. View

2.
Simonen P, Gylling H, Miettinen T . The validity of serum squalene and non-cholesterol sterols as surrogate markers of cholesterol synthesis and absorption in type 2 diabetes. Atherosclerosis. 2007; 197(2):883-8. DOI: 10.1016/j.atherosclerosis.2007.08.003. View

3.
Miettinen T, Vuoristo M, Nissinen M, Jarvinen H, Gylling H . Serum, biliary, and fecal cholesterol and plant sterols in colectomized patients before and during consumption of stanol ester margarine. Am J Clin Nutr. 2000; 71(5):1095-102. DOI: 10.1093/ajcn/71.5.1095. View

4.
Miettinen T . Cholesterol metabolism during ketoconazole treatment in man. J Lipid Res. 1988; 29(1):43-51. View

5.
Vanhanen H, Kajander J, Lehtovirta H, Miettinen T . Serum levels, absorption efficiency, faecal elimination and synthesis of cholesterol during increasing doses of dietary sitostanol esters in hypercholesterolaemic subjects. Clin Sci (Lond). 1994; 87(1):61-7. DOI: 10.1042/cs0870061. View